Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.48 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.47 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.47 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.47 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL380483 | 1.00 | HCAR2 (0.48) | HCAR2EIF2AK2CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL4604993 | 0.85 | NPC1 (0.40) | HCAR2EIF2AK2CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL4604987 | 0.85 | NPC1 (0.40) | HCAR2EIF2AK2CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL7890266 | 0.82 | CES2 (0.41) | HCAR2KMT2ANPC1GAAMEN1 | |
| SCHEMBL7890262 | 0.82 | CES2 (0.41) | HCAR2KMT2ANPC1GAAMEN1 | |
| SCHEMBL4389421 | 0.78 | HCAR2 (0.47) | HCAR2EIF2AK2CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL1463003 | 0.78 | HCAR2 (0.47) | HCAR2EIF2AK2CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL4389413 | 0.78 | HCAR2 (0.47) | HCAR2EIF2AK2CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL1463002 | 0.78 | HCAR2 (0.47) | HCAR2EIF2AK2CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL4081161 | 0.78 | KCNA3 (0.46) | HCAR2KMT2ANPC1GAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113024573-A | Epodophyllotoxin derivative, preparation method and application thereof in preparation of antitumor drugs | 江苏百奥信康医药科技有限公司 | 2021-06-25 | — | — | CN | claimed |
| CN-113024573-B | Epodophyllotoxin derivative, preparation method and application thereof in preparation of antitumor drugs | 江苏百奥信康医药科技有限公司 | 2022-04-05 | — | — | CN | disclosed |
| CN-113024573-A | Epodophyllotoxin derivative, preparation method and application thereof in preparation of antitumor drugs | 江苏百奥信康医药科技有限公司 | 2021-06-25 | — | — | CN | disclosed |
| US-20210179603-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2021-06-17 | — | — | US | disclosed |
| US-10968213-B2 | Cyclopropanamine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-06 | — | — | US | disclosed |
| US-10717738-B2 | Pyrimidinone and its derivatives inhibiting factor XIa | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-07-21 | — | — | US | disclosed |
| EP-3290413-B9 | PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS | ONO PHARMACEUTICAL CO (JP) | 2020-04-29 | — | — | EP | disclosed |
| EP-3290413-B1 | PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS | ONO PHARMACEUTICAL CO (JP) | 2019-11-13 | — | — | EP | disclosed |
| US-20190315735-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2019-10-17 | — | — | US | disclosed |
| US-10414761-B2 | Cyclopropanamine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-09-17 | — | — | US | disclosed |
| EP-1051176-A1 | SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS | Aventis Pharmaceuticals Products Inc. (US) | 2000-11-15 | — | — | EP | disclosed |
| EP-1040103-A1 | ANILIDE DERIVATIVE, PRODUCTION AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2000-10-04 | — | — | EP | disclosed |
| EP-1039899-A2 | PHARMACEUTICAL COMPOSITION FOR ANTAGONIZING CCR5 COMPRISING ANILIDE DERIVATIVE | Takeda Chemical Industries, Ltd. (JP) | 2000-10-04 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
| WO-1999037304-A1 | SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-07-29 | — | — | WO | disclosed |
| WO-1999032100-A2 | PHARMACEUTICAL COMPOSITION FOR ANTAGONIZING CCR5 COMPRISING ANILIDE DERIVATIVE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-07-01 | — | — | WO | disclosed |
| WO-1999032468-A1 | ANILIDE DERIVATIVE, PRODUCTION AND USE THEREOF | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-07-01 | — | — | WO | disclosed |
| EP-0170524-B1 | NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-07-15 | — | — | EP | disclosed |
| US-4968698-A | FUNGICIDES, ANTIPROTOZOA AGENTS | BURROUGHS WELLCOME CO. (US) | 1990-11-06 | — | — | US | disclosed |
| EP-0170524-A2 | Nitrogen containing heterocyclic compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1986-02-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315735-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | KDM1A, KDM1B, KDM2A | HCAR2 3714/4885EIF2AK2 4087/4885CSNK2A2 521/4885 |
| US-20210179603-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | KDM1A, KDM1B, KDM2A | HCAR2 3714/4885EIF2AK2 4087/4885CSNK2A2 521/4885 |
| US-10717738-B2 | Pyrimidinone and its derivatives inhibiting factor XIa | F11, TFPI, F10 | HCAR2 3172/4885EIF2AK2 2031/4885CSNK2A2 2037/4885 |
| US-10968213-B2 | Cyclopropanamine compound and use thereof | KDM1A, KDM1B, KDM2A | HCAR2 3714/4885EIF2AK2 4087/4885CSNK2A2 521/4885 |
| US-10414761-B2 | Cyclopropanamine compound and use thereof | KDM1A, KDM1B, KDM2A | HCAR2 3714/4885EIF2AK2 4087/4885CSNK2A2 521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.